Bummer! This is the high dose biotin.
MedDay Pharmaceuticals‘ MD1003 did not ease functional disability or its progression in patients with non-active progressive multiple sclerosis, Phase 3 clinical trial data shows.
The SPI2 Phase 3 study (NCT02936037) sought to confirm the positive results of a first Phase 3 trial called MS-SPI (NCT02220933), but failed to do so.
“We are clearly disappointed that SPI2 did not meet its primary and secondary endpoints. Going forward, we will continue to evaluate the trial data and confer with regulators,” Catherine Moukheibir, CEO of MedDay Pharmaceuticals, said in a press release.
https://multiplesclerosisnewstoday.c...ple-sclerosis?
MedDay Pharmaceuticals‘ MD1003 did not ease functional disability or its progression in patients with non-active progressive multiple sclerosis, Phase 3 clinical trial data shows.
The SPI2 Phase 3 study (NCT02936037) sought to confirm the positive results of a first Phase 3 trial called MS-SPI (NCT02220933), but failed to do so.
“We are clearly disappointed that SPI2 did not meet its primary and secondary endpoints. Going forward, we will continue to evaluate the trial data and confer with regulators,” Catherine Moukheibir, CEO of MedDay Pharmaceuticals, said in a press release.
https://multiplesclerosisnewstoday.c...ple-sclerosis?
Comment